Iveric Bio

Iveric drug approved for type of vision loss as rival’s safety draws scrutiny
Iveric drug approved for type of vision loss as rival’s safety draws scrutiny
BioPharma Dive
Iveric Bio
geographic atrophy
FDA
Izervay
Astellas
Flag link:
5 FDA decisions to watch in the third quarter
5 FDA decisions to watch in the third quarter
BioPharma Dive
FDA
SAGE Therapeutics
Biogen
zuranolone
Eisai
Leqembi
Sanofi
AstraZeneca
nirsevimab
Iveric Bio
Zimura
Alnylam
Onpattro
Flag link:
Biotech M&A is picking back up - here are the latest deals
Biotech M&A is picking back up - here are the latest deals
BioPharma Dive
Novartis
Chinook Therapeutics
Paratek
Sobi
CTI BioPharma
Astellas
Iveric Bio
Assertio Holdings
Spectrum Pharmaceuticals
Merck
Prometheus Biosciences
Pfizer
Seagen
Sanofi
Provention Bio
Sun Pharma
Concert Pharmaceuticals
BioNTech
InstaDeep
AstraXeneca
CinCor Pharma
Ipsen
Albireo
Chiesi
Amryt
Moderna Therapeutics
OriCiro Genomics
Flag link:
With Iveric Bio buyout, Astellas CEO Okamura acted on the company's mantra to be 'aggressive'
With Iveric Bio buyout, Astellas CEO Okamura acted on the company's mantra to be 'aggressive'
Fierce Pharma
Astellas
M&A
Iveric Bio
Naoki Okamura
Pharma CEOs
Flag link:
Bayer, Amgen looked at Iveric before agreeing to Astellas sale
Bayer, Amgen looked at Iveric before agreeing to Astellas sale
Seeking Alpha
Astellas
Iveric Bio
Bayer
Amgen
M&A
Flag link:
2023’s biggest launches: the story so far
2023’s biggest launches: the story so far
EP Vantage
drug launches
AbbVie
Almirall
Apellis Pharmaceuticals
Astellas
AstraZeneca
Biogen
CRISPR Therapeutics
Daiichi Sankyo
Eli Lilly
Genmab
GSK
Iveric Bio
Pfizer
Roche
SAGE Therapeutics
Sanofi
Sarepta Therapeutics
Shionogi
Swedish Orphan Biovitrum
Vertex Pharmaceuticals
Flag link:
Astellas to acquire eye drug developer Iveric Bio for $5.9B
Astellas to acquire eye drug developer Iveric Bio for $5.9B
BioPharma Dive
Astellas
M&A
Iveric Bio
eye health
Flag link:
FDA accepts Iveric Bio's NDA, grants priority review for GA drug
FDA accepts Iveric Bio's NDA, grants priority review for GA drug
Endpoints
Iveric Bio
FDA
geographic atrophy
Apellis Pharmaceuticals
avacincaptad pegol
Flag link:
Iveric hits again in pivotal eye disease program, keeping it on Apellis' tail in race to market
Iveric hits again in pivotal eye disease program, keeping it on Apellis' tail in race to market
Fierce Biotech
Iveric Bio
Apellis Pharmaceuticals
clinical trials
FDA
dry eye disease
geographic atrophy
Flag link:
Why Iveric Bio Is Skyrocketing 24% Today
Why Iveric Bio Is Skyrocketing 24% Today
Motley Fool
Iveric Bio
geographic atrophy
Zimura
Flag link:
IVERIC bio announces fast track designation from US FDA for Zimura to treat geographic atrophy secondary to dry age-related macular degeneration
IVERIC bio announces fast track designation from US FDA for Zimura to treat geographic atrophy secondary to dry age-related macular degeneration
Pharmaceutical Business Review
Iveric Bio
FDA
Zimura
fast track
dry age-related macular degeneration
Flag link:
Iveric bio the latest to be hit by COVID-19 as it delays a key trial
Iveric bio the latest to be hit by COVID-19 as it delays a key trial
Fierce Biotech
Iveric Bio
Zimura
COVID-19
clinical trials
dry age-related macular degeneration
Flag link:
Ophthotech (now Iveric) hits eye drug goals as shares jump for tiny biotech
Ophthotech (now Iveric) hits eye drug goals as shares jump for tiny biotech
Fierce Biotech
Iveric Bio
Ophthotech
Zimura
gene therapies
dry age-related macular degeneration
Flag link:
Ophthotech becomes Iveric in pivot to gene therapies
Ophthotech becomes Iveric in pivot to gene therapies
Fierce Biotech
Ophthotech
Iveric Bio
gene therapy
Flag link: